ID

21921

Descrizione

The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be obtained from the current phase III trials . The study aims to enroll fourteen patients (seven of each APOE genotype). Each patient will receive a single oral dose of 4mg of RSG XR in the morning under fasted conditions and PK samples will be taken up to 36h. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1

collegamento

https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1

Keywords

versioni (2)
  1. 08/05/17 08/05/17 -
  2. 20/05/17 20/05/17 -
Caricato su

8 maggio 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Study Conclusion Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941

Inglese

Study Conclusion Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941

1 moduli  
Study Conclusion
Descrizione

Study Conclusion

Alias
UMLS CUI-1
C1707478
UMLS CUI-2
C0008976
Date of subject completion or withdrawal
Descrizione

Date of completion

Tipo di dati

date

Alias
UMLS CUI [1]
C0011008
Was the subject withdrawn from the study?
Descrizione

Withdrawal

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2349954
If yes, check one primary reason for withdrawal:
Descrizione

Reason for withdrawal

Tipo di dati

integer

Alias
UMLS CUI [1,1]
C2349954
UMLS CUI [1,2]
C0392360
Specify "Investigator discretion":
Descrizione

Specification

Tipo di dati

text

Alias
UMLS CUI [1]
C2348235
Ritorna all'inizio della pagina

Similar models

Study Conclusion Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Study Conclusion
C1707478 (UMLS CUI-1)
C0008976 (UMLS CUI-2)
Date of completion
Item
Date of subject completion or withdrawal
date
C0011008 (UMLS CUI [1])
Withdrawal
Item
Was the subject withdrawn from the study?
boolean
C2349954 (UMLS CUI [1])
Item
If yes, check one primary reason for withdrawal:
integer
C2349954 (UMLS CUI [1,1])
C0392360 (UMLS CUI [1,2])
Reason for withdrawal
Code List
If yes, check one primary reason for withdrawal:
CL Item
Adverse event -> Record details on the Non-Serious Adverse Events or Serious Adverse Event pages as appropriate  (1)
CL Item
Protocol deviation (2)
CL Item
Subject reached protocol defined stopping criteria (3)
CL Item
Study closed/terminated (4)
CL Item
Lost to follow-up (5)
CL Item
Investigator discretion (Only check if none of the other primary reasons are appropriate) (6)
CL Item
Withdrew consent (Only check if none of the other primary reasons are appropriate) (7)
Specification
Item
Specify "Investigator discretion":
text
C2348235 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial